Canaccord ups Regeneron to buy, sees high-dose Eylea re-igniting sales (REGN)

fda approved


fda approved

Kameleon007

Canaccord Genuity has raised its rating on Regeneron (NASDAQ:REGN) to buy, commenting that the FDA’s decision to approve a higher dose of the company’s drug Eylea will help re-ignite sales and take back market share from Roche’s (OTCQX:RHHBY

Leave a Reply

Your email address will not be published. Required fields are marked *